Skip to content
Back to meeting Original
Martin ZapataLaguado· @zapatalaguadomd · X·· 2 days agoScore70

disitamab

Body

#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC.81% HER2-positive Promising antitumor activity Higher HER2 expression may predict response. @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily

33 views · 1 like · 1 repost · 0 replies

Source: Martin ZapataLaguado · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.